论文部分内容阅读
目的:研究利妥昔单抗对Navelbine诱导淋巴瘤细胞凋亡的增敏作用,并探讨其可能的作用机制。方法:体外培养Daudi、Ramos、Nama-lwa和Raji细胞,采用XTT法测定Navelbine在Rituximab作用前后的IC50及细胞增殖抑制率,并绘出细胞增殖抑制的量效曲线,比较Navelbine单药及Navelbine与rituximab两药联合作用曲线的关系。采用蛋白质印迹法测定Daudi、Ramos、Raji和Namlwa细胞经Rituximab作用24h后Bcl-2的表达水平。结果:在Daudi、Na-malwa和Raji细胞株中,经Rituximab作用24h后,Navelbine的IC50明显降低;在Daudi、Namal-wa和Raji细胞株中,Navelbine和Rituximab联合作用的细胞增殖抑制曲线左移,表明两者有协同作用。在Namalwa和Raji细胞株中,经Ritux-imab作用24h后,可见Bcl-2蛋白表达水平下调。结论:Rituximab对Navelbine诱导淋巴瘤细胞凋亡有明显的增敏作用。在Namalwa和Raji细胞株,经Rituximab作用24h后可见Bcl-2表达水平下调,可能是Rituximab增敏的机制之一。
Objective: To investigate the sensitizing effect of rituximab to Navelbine-induced lymphoma cell apoptosis and to explore its possible mechanism. Methods: The IC50 and cell proliferation inhibition rate of Navelbine before and after Rituximab treatment were determined by XTT method. The dose-effect curves of inhibition of cell proliferation were plotted. Compared Navelbine monotherapy with Navelbine and Ravel cells Relationship between rituximab and two drugs. The expression of Bcl-2 in Daudi, Ramos, Raji and Namlwa cells treated with Rituximab for 24h was determined by Western blotting. Results: In Daudi, Na-malwa and Raji cell lines, the IC50 of Navelbine decreased significantly after treated with Rituximab for 24 hours. In Daudi, Namal-wa and Raji cell lines, the cell proliferation inhibition curve of Navelbine and Rituximab shifted to the left , Indicating that the two have a synergistic effect. In Namalwa and Raji cell lines, the expression of Bcl-2 protein was down-regulated after treated with Ritux-imab for 24 h. Conclusion: Rituximab can sensitize Navelbine-induced lymphoma cells to apoptosis. In Namalwa and Raji cell lines, the down-regulation of Bcl-2 expression after 24h Rituximab treatment may be one of the mechanisms of Rituximab sensitization.